Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. - Wikidata - awgldk - TriplyDB

Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.

Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.

http://www.wikidata.org/entity/Q45869806

about

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors Herpes simplex virus type 1 single strand DNA binding protein and helicase/primase complex disable cellular ATR signaling.Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.Oncolytic virotherapy for urological cancers.Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent.

P2860

Q26998111-569C3472-4594-4D8C-BAAB-289E0911D013 Q27303714-68DA10B3-63E6-47BD-B03D-F4ACD8CFA958 Q27329466-15FB99B8-D456-4B9B-BB5B-A27CCA2EE085 Q35008795-287414B3-8776-434A-8107-9FCAD9733A17 Q35691410-D5C2182C-E166-41F4-9A3D-06B2ECFBC732 Q36099082-4EBF9A8B-28E3-4E4A-9F3B-16386BAED414 Q36109700-35966043-1521-4DB9-8623-D3861280047A Q36549443-5CD5E174-33CC-4208-96AC-602BFB79E923 Q36644898-AEF96147-D149-4B4A-A8BB-664CEA2CD857 Q36849213-A8E0615B-D568-4A97-9A47-693B0AF9D3D9 Q37346179-982A485C-938E-4E1A-9778-AD0077C1EB38 Q37459624-3DBDA5C9-C6F5-40AB-AE75-E3226FF8947D Q38842126-D18400D5-D740-406C-8C09-61EAAD3DFC05 Q40284855-BEDB835F-AAB9-4BDC-91B5-897552D380B6 Q41528492-A1B73B10-389D-41DF-8BAD-FA9943597BF2

P2860

Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.

http://www.wikidata.org/entity/Q45869806

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Increased oncolytic efficacy f ...... he replicative cycle of HSV-1.

@en

Increased oncolytic efficacy f ...... he replicative cycle of HSV-1.

@nl

type

label

Increased oncolytic efficacy f ...... he replicative cycle of HSV-1.

@en

Increased oncolytic efficacy f ...... he replicative cycle of HSV-1.

@nl

prefLabel

Increased oncolytic efficacy f ...... he replicative cycle of HSV-1.

@en

Increased oncolytic efficacy f ...... he replicative cycle of HSV-1.

@nl

P1433

Q45869806-3C46CAF1-E4FB-426B-A0C7-EA23637D0D2E

P1476

Q45869806-7D50B72C-596C-4510-9704-7516B68643B9

P2093

Q45869806-0F80794F-D16B-445A-9873-40B0EB292347

Q45869806-194A20E5-A2C0-4697-9BCA-182A2F1BD014

Q45869806-7A442C93-18E8-4A66-A1FA-496462B4DD79

Q45869806-8DEA7B33-D2FB-4731-A549-F5255B1F5EAC

Q45869806-99FF6DCB-3A4B-4B94-A37C-1E6D2FC1EDB8

Q45869806-D1485440-3884-46D5-95FD-A709CF0CC245

Q45869806-DB53F37A-B427-492F-8937-ABE56ED9882D

P2860

Q45869806-0C180EAE-CEAC-473D-B198-922D191DACB4

Q45869806-138762EB-4004-4B28-9EAF-977A96C92A0F

Q45869806-1D9FEFAB-388E-4D14-8735-744850A16440

Q45869806-1E576E83-0620-4CC5-ADD6-057C74806B19

Q45869806-251CF0FB-C53E-4E55-9CEB-00CC218ABF25

Q45869806-27CDED38-F53C-4946-B1AD-00A738D82DDB

Q45869806-49C0DDEF-8D63-451E-BE60-2FA409F21AE3

Q45869806-4FF684F5-ACFF-4709-BFEF-FE573015FAAA

Q45869806-5B1B162C-69F4-4AD7-A5CD-3416D569F65D

Q45869806-5ED22C96-3755-4665-A40E-13DDA9B5C65D

P2888

Q45869806-1D002D5B-C6B7-4BC3-8891-47A56D3346DE

P304

Q45869806-67E131F3-5925-49D2-BA00-C7E2F0B81C46

P31

Q45869806-D4D42987-31D6-4D50-BD64-D1C569099A10

P356

Q45869806-903B0EF1-578B-4844-8B66-C0754E9A5372

P433

Q45869806-FC4005EA-477E-4EB1-8A87-700655ED7105

P478

Q45869806-B5C1F91A-4897-4E30-8D04-0395B13AA322

P50

Q45869806-3958D053-AC23-48CC-BF22-CB8E2A4E5766

P577

Q45869806-C41A38E6-7234-4EBB-B3A3-82D4E5CBC580

P5875

Q45869806-8B413E0E-38E1-4C05-9909-59398FFCDC41

P6179

Q45869806-0F13D861-BD83-4DC3-B722-D85E73F487A3

P698

Q45869806-E0519278-591D-463B-B19D-3ED4E50D8479

P356

P1433

P1476

Increased oncolytic efficacy f ...... he replicative cycle of HSV-1.

@en

P2093

G Y Gillespie

http://www.w3.org/2001/XMLSchema#string

J M Markert

http://www.w3.org/2001/XMLSchema#string

M Y Shao

http://www.w3.org/2001/XMLSchema#string

R F Sood

http://www.w3.org/2001/XMLSchema#string

R R Weichselbaum

http://www.w3.org/2001/XMLSchema#string

S J Advani

http://www.w3.org/2001/XMLSchema#string

S Samuel

http://www.w3.org/2001/XMLSchema#string

P2860

Mammalian GADD34, an apoptosis- and DNA damage-inducible gene

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer.

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.

P2888

P304

1098-1102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/GT.2011.61

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Roizman

P577

2011-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51099772

http://www.w3.org/2001/XMLSchema#string

P6179

1026234370

http://www.w3.org/2001/XMLSchema#string

P698

21544094

http://www.w3.org/2001/XMLSchema#string